Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $408.18, moving +0.72% from the previous trading session. The stock trailed the S&P 500, which registered a daily gain of 1.1%.

Fox News contributor and medical expert Dr. Kelly Powers has died following ... and participated in residency programs at Georgetown and Boston University. Powers went on to make frequent ...

Vertex Pharmaceuticals Inc. notched two FDA victories ... for its drugs and likely boosting its own future revenue. The Boston-based drugmaker heard back from the FDA ahead of its scheduled ...

Vertex Pharmaceuticals is trying to diversify its product portfolio. One of the programs it's working on aims to treat pain in a few contexts. There's reason to believe that it won't be effective ...

Vertex Pharmaceuticals (NASDAQ: VRTX) fell by 13% on Dec. 19, when the rare-disease drug developer reported some lackluster results from a late-stage clinical trial. But far from being a reason to ...

Vertex Pharmaceuticals has received FDA approval for Alyftrek in cystic fibroris, six years and older. The approval increases the company’s CF opportunity by around 6,000 patients at launch.

Vertex Pharmaceuticals stock was heading for a double-digit gain this year until recent weeks. The company is approaching an important turning point -- one that could set the tone for revenue growth.

The announcement comes directly from Vertex Pharmaceuticals (NASDAQ:VRTX) Incorporated, with the signatory on the report being Jonathan Biller, the Executive Vice President and Chief Legal Officer ...